depression Parkinson's disease
Conditions
Interventions
None listed
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: For the present study, we will select patients from the PPP and PRIME cohorts and from clinical samples from neurologists embedded in Parkinsonnet and/or in the service area of the RadboudUMC. The PPP study is a pro-spective, longitudinal, single-center cohort study of the Radboudumc in the Netherlands which started in October 2017. Enrollment period will take 2 years, in which a total of 650 adult patients diagnosed with PD with
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: Exclusion criteria: • Contraindications for MRI, e.g., claustrophobia, presence of an active implant, pacemaker, insulin pump, neurostimulator, ossicle prosthesis, pregnancy, and/or other medical device or other non-removable metal part incompatible with MRI. • Contraindications for PET e.g., inability to lie flat or lie still for the duration of the scan, claustrophobia (occasionally). • Use of medication or drugs with evident DAT-binding like methylphenidate, buproprion, amphetamines, cocaine that cannot be discontinued according to the PET-protocol. Note that we allow use of anti-depressants with the exception of those antidepressants with a high DAT binding defined as a relatively low Ki of
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences between (anhedonic and non-anhedonic) depressed PD patients and non-depressed PD patients in: (1) Baseline DAT-availability measured with PET; (2) Functional connectivity from seeds with aberrant DAT-availability compared to non-depressed PD. | — |
Secondary
| Measure | Time frame |
|---|---|
| Differences between (anhedonic and non-anhedonic) depressed PD patients and non-depressed PD patients in effort-reward weighting on an effort-reward-choice-task (ERCT), fMRI-based BOLD signal when performing the ERCT during the decisional phase, fMRI-based BOLD signal when performing a reinforcement learning task, neuromelanin, and subjective self-report measurements assessing depression, anhedonia, apathy and anxiety. | — |
Countries
Netherlands
Outcome results
None listed